CASP3 and hepatocellular carcinoma: Specifically, oral administration of TQ (20 mg/kg) enhanced the effectiveness of cisplatin in hepatocellular carcinoma (HCC) treatment by regulating the GRP78/CHOP/caspase-3 pathway [76].